Skip to contentT
Travere Therapeutics, Inc.
T
TVTXTravere Therapeutics, Inc. Q2 2015 · 10-Q
Revenue$24.07M$24.07M+319.2% vs Q2 2014 Net Income-$25.53M-$25.53MN/M vs Q2 2014 EPS Diluted-$0.73-$0.73N/M vs Q2 2014 Operating Income-$6,944,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$8,014,000N/M Margins · derivedOperating margin-28.9%+270.4 pt vs Q2 2014
Net margin-106.1%
ended Jun 30, 2015 · filed Aug 10, 2015 · 41 d after period end